Wiltrom Co. Ltd. · TPEX:6767
Wiltrom — Q1-Q3 2025 Earnings Presentation
12 slides from Wiltrom's earnings presentation, December 2025
Slide 1: Wiltrom Co., Ltd
Stock Number: 6767 Wiltrom Co., Ltd Presenter: Liang Huang-Chien, Chairman 0
Slide 2: Safe Harbor Notice
Safe Harbor Notice Except for historical information set forth herein, this presentation contains certain forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from what may be expressed or implied by such statements. Investors sh
Slide 3: Outline
Outline Company Profile and Business Development Operational and Financial Overview 2
Slide 4: Our Journey & Milestones
Our Journey & Milestones Building a complete minimally invasive spine surgery platform 2009 Spun off from ITRI, a leading research institute with an initial paid-in capital of NT$18 million. 2014 First to secure TFDA & EU approval for our proprietary spinal screws; Awarded the 11th National Innovati
Slide 5: Product Portfolio & Global Market
Product Portfolio & Global Market Actively Expanding Our Global Footprint TAM: US$11.0 Billion Expanding our spine care portfolio TAM: US$1.15 Billion Spinal Fusion Vertebral Augmentation System: Tripod-Fix Interbody Fusion System Bone Cement 1. Growth is propelled by an aging population, a rising i
Slide 6: Outline
Outline Company Profile and Business Development Operational and Financial Overview 5
Slide 7: Operating Revenue in Recent Years
Operating Revenue in Recent Years Steady Revenue Growth (In Thousands of New Taiwan Dollars) 350,000 334,730 300,000 282,538 247,450 250,000 206,864 200,000 144,499 150,000 102,368 100,000 75,261 59,829 50,000 0 2018 2019 2020 2021 2022 2023 2024 Q1-Q3 / 2025 Q1-Q3/2025 Year 2018 2019 2020 2021 2022
Slide 8: Historical Financial Results
Historical Financial Results 2025 Operating Losses Narrow as EU PMCF Expenses Wind Down (In Thousands of New Taiwan Dollars) ACCOUNT 2020 2021 2022 2023 2024 Q1~Q3 / 2025 OPERATING REVENUE 102,368 144,499 206,864 282,538 334,730 247,450 GROSS PROFIT 66,000 102,390 156,607 222,598 263,768 194,234 OPE
Slide 9: Consolidated Operating Revenue (by Product Category)
Consolidated Operating Revenue (by Product Category) Driven Mainly by Spinal Fusion System Products (In Thousands of New Taiwan Dollars) Q1-Q3 / 2025 (1st) Spinal Fusion System 76% Total Revenue: 187,238 thousand Vertebral Body Augmentation System 19.1% Spinal Fusion System Service Revenue (2nd) Ver
Slide 10: Consolidated Operating Revenue (Regional Contribution)
Consolidated Operating Revenue(Regional Contribution) Deepening Presence in the Taiwan Market and Expanding Across Asia (In Thousands of New Taiwan Dollars) Q1-Q3 / 2024 Q1-Q3 / 2025 Asia 5.2% Asia 10.8% Central and South America Taiwan 85.4% 2.8% Taiwan 81.9% Central and South America 2.3% Europe a
Slide 11: Sales Distribution by Market: Taiwan and International
Sales Distribution by Market: Taiwan and International 2020 – 2025Q3 (In Thousands of New Taiwan Dollars) Sales by Market Q1-Q3 / 2025 100% 80% 60% Foreign 18% 40% Taiwan 20% 82% 0% 2020 2020 2020 2020 2020 Q1-Q3 / 2025 2020 2020 2020 2020 2020 Q1-Q3 / 2025 Foreign 15% 8% 10% 8% 17% 18% Taiwan 85% 9
Slide 12: Thank You
Thank You wittrom WEEEFOM sersestscaioe